<?xml version="1.0" encoding="UTF-8"?>
<p id="Par7">There is some data regarding use of dipeptidyl peptidase 4 (DPP4) inhibitors from previous viral epidemics. DPP4 is the prime receptor for Middle East respiratory syndrome coronavirus responsible for its entry into cell [
 <xref ref-type="bibr" rid="CR19">19</xref>]. Hence the possibility of DPP4 facilitating the entry of SARS CoV-2 into the cell cannot be ruled out. In that context, it is an interesting postulation that widespread use of DPP4 inhibitors in India and many other countries might be protecting individuals with diabetes from this infection. On the other hand, DPP4 inhibitors can potentially interfere with immune response which may be harmful, but clinical data from DPP4 inhibitors has shown that this is generally not the case [
 <xref ref-type="bibr" rid="CR20">20</xref>].
</p>
